Chimerix(CMRX) - 2024 Q2 - Quarterly Results

Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update – Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – – ONC206 Phase 1 PK and Safety Data Demonstrate Dose Proportional Exposure with No Dose Limiting Toxicity to Date – – Dordaviprone Filed for Provisional Determination with Therapeutic Goods Administration in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., August 13, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASD ...